Author - admin4821

Annandale, VA; August 5, 2020 CARE-ID has made very good progress toward its total enrollment goal with 20% achieved to date. With these initial participants already signed up and receiving their first infusions, CARE-ID is off to a good start for this landmark clinical research study. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful results in the laboratory setting. As of August 3rd, over 200 participants have enrolled in the study nation-wide and have received the one-time, one-hour infusion in the outpatient setting. To continue making its progress, CARE-ID is looking for additional adults in the Northern Virginia area ages 18 or older to participate in the study who have recently tested positive for COVID-19 and are not hospitalized.

• Read about the NIH working with clinical sites on antibody treatment study
• Read more about CARE-ID’s involvement in the BLAZE-1 Study

Designer antibodies could battle COVID-19 before vaccines arrive Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation. While the world is transfixed by the high-stakes race to develop a COVID-19 vaccine, an equally crucial competition is heating up to produce targeted antibodies that could provide an instant immunity boost against the virus. Clinical trials of these monoclonal antibodies, which could both prevent and treat the disease, are already underway and could produce signs of efficacy in the next few months, perhaps ahead of vaccine trials.

• Read entire article

Annandale, VA; June 29, 2020 CARE-ID has begun recruiting and treating patients in a clinical research study to evaluate the safety and effectiveness of LY-CoV555 in patients with early mild to moderate COVID-19. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful laboratory studies. CARE-ID is looking for adults ages 18 or older to participate in this study who have recently tested positive for COVID-19 and are not hospitalized.

• Watch an in-depth conversation on Lilly’s antibody treatment research here
• Read more about CARE-ID’s involvement in the BLAZE-1 Study